|
Low grade glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, the clear connection between increased survival rates and immune receptor-IDH1 mutant complementarities may also, partially, explain the better LGG prognosis for patients with IDH1 mutants.
|
31740784 |
2020 |
|
Low grade glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Preserved GABRD expression was independently associated with longer OS (HR: 0.799, 95%CI: 0.691-0.925, p = 0.003) in IDH WT LGG.
|
31545245 |
2019 |
|
Low grade glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutation is associated with a higher preoperative seizure incidence in low-grade glioma: A systematic review and meta-analysis.
|
29414139 |
2018 |
|
Low grade glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In low-grade glioma (LGG) and glioblastoma cohorts of TCGA, significantly higher PD-L1 gene expression levels were evident in IDH-wt compared with IDH-mut samples (LGG: N = 516; P = 1.933e-11, GBM: N = 161; P < 0.009).
|
28531337 |
2017 |
|
Low grade glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed 112 IDH1 wild-type (IDH1WT) versus 399 IDH1MUT low-grade glioma and 157 IDH1WT versus 9 IDH1MUT glioblastoma samples.
|
28467784 |
2017 |
|
Low grade glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Isocitrate dehydrogenase 1 (IDH1) mutation is common in low-grade glioma (approximately 80%) and acute myeloid leukemia (approximately 10%).
|
28403884 |
2017 |
|
Low grade glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Deep Learning based Radiomics (DLR) and its usage in noninvasive IDH1 prediction for low grade glioma.
|
28710497 |
2017 |
|
Low grade glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CMRO<sub>2</sub> was decreased (P = .037) in low-grade glioma with a mutated IDH gene, and MTI was significantly increased in glioma grade III with IDH mutation (P = .013) when compared with the IDH wild-type counterparts.
|
27982759 |
2017 |
|
Low grade glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, mutations in isocitrate dehydrogenase 1/2 (IDH1/2) were discovered in 70% of low-grade glioma and secondary glioblastoma multiforme.
|
27649069 |
2017 |
|
Low grade glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IDH mutation is associated with higher risk of malignant transformation in low-grade glioma.
|
26780338 |
2016 |
|
Low grade glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A mutation in isocitrate dehydrogenase-1 (IDH1) was found in 72.9% of LGG, and this mutation was positively correlated with methylation of O6-methylguanine-DNA methyltransferase (MGMT) (p=0.02).
|
26276726 |
2015 |
|
Low grade glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among the 46 patients with IDH1 wild-type glioma, 35 and 11 had high- and low-grade glioma, respectively.
|
25862748 |
2015 |
|
Low grade glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 311 adult patients with LGG were enrolled in our study with both clinical data and IDH1/2 mutation data available.
|
25524848 |
2015 |
|
Low grade glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Isocitrate dehydrogenase (IDH) genes 1 and 2 are frequently mutated in acute myeloid leukaemia (AML), low-grade glioma, cholangiocarcinoma (CC) and chondrosarcoma (CS).
|
23863747 |
2013 |
|
Low grade glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IDH1/IDH2 mutation was detected in 32 primary tumors, with 25 low-grade gliomas and 6 anaplastic gliomas harboring IDH1 mutation and 1 low-grade glioma harboring IDH2 mutation.
|
23840696 |
2013 |
|
Low grade glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Somatic mutations in the isocitrate dehydrogenase 1 (IDH1) gene have been frequently found in low-grade glioma and secondary glioblastoma and are associated with a significantly younger age at diagnosis and a superior overall survival.
|
22199315 |
2011 |
|
Low grade glioma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Subsequent studies have confirmed recurrent IDH1 and IDH2 mutations in up to 70% of low-grade glioma and secondary GBM, as well as in 10% of acute myeloid leukemia (AML) cases.
|
20692206 |
2010 |